 |
0 Diseases |  |
4 Trials |
|
4 Trials |  |
74 News |  |
| 12» |
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 13, 2024
P3, N=669, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Sep 2024 --> Sep 2025
- | thioguanine / Generic mfg.
Trial completion date: Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (clinicaltrials.gov) - Jul 22, 2024
P3, N=280, Active, not recruiting, Sponsor: Children's Oncology Group
Trial completion date: Sep 2024 --> Sep 2025 Trial completion date: Jun 2024 --> Jul 2025
- | lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Trial completion: AALL0631: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 15, 2024
P3, N=218, Completed, Sponsor: Children's Oncology Group
Trial completion date: Jun 2024 --> Jul 2025 Active, not recruiting --> Completed
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Trial completion date: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Apr 5, 2024
P3, N=1895, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- | Xospata (gilteritinib) / Astellas, Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Mylotarg (gemtuzumab ozogamicin) / Pfizer
Enrollment closed: A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (clinicaltrials.gov) - Mar 12, 2024
P3, N=1400, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Leunase (L-asparaginase) / Kyowa Kirin
Asparagine deprivations enhance CD8+ T cell antitumor activity and ICB immunotherapy via ROS-mediated NFAT nuclear localization (Section 47) - Mar 5, 2024 - Abstract #AACR2024AACR_2428;
In patients with nasopharyngeal carcinoma (NPC), leunase therapy enhances the cytokines production and activation of CD8+ T cell. In summary, our findings offer valuable insights into how T cells adapt to changes in their nutritional environment.
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 18, 2023
P3, N=669, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
In summary, our findings offer valuable insights into how T cells adapt to changes in their nutritional environment. Trial completion date: Apr 2024 --> Sep 2024
- | lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Trial completion date: AALL0631: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 6, 2023
P3, N=218, Active, not recruiting, Sponsor: Children's Oncology Group
Trial completion date: Apr 2024 --> Sep 2024 Trial completion date: Jul 2023 --> Jun 2024
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 23, 2023
P3, N=669, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jul 2023 --> Jun 2024 Trial completion date: Jun 2023 --> Apr 2024
- DP-9024 / Deciphera
DP-9024, an investigational small molecule modulator of the integrated stress response kinase GCN2, synergizes with asparaginase therapy in leukemic tumors (Section 15; Poster Board #16) - Mar 14, 2023 - Abstract #AACR2023AACR_7339;
The ISR kinase GCN2 was identified as a resistance mechanism to ASNase in ASNS-low leukemic cells. Inhibition of the ISR pathway through the potent and selective small molecule modulator of GCN2, DP-9024, synergized with ASNase and re-sensitized leukemic cells to amino acid withdrawal in vitro as well as in leukemic xenograft models in vivo.
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 25, 2023
P3, N=669, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Inhibition of the ISR pathway through the potent and selective small molecule modulator of GCN2, DP-9024, synergized with ASNase and re-sensitized leukemic cells to amino acid withdrawal in vitro as well as in leukemic xenograft models in vivo. Trial completion date: Dec 2030 --> Jun 2023
- | thioguanine / Generic mfg.
Trial completion date, Trial primary completion date: Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (clinicaltrials.gov) - Jun 15, 2022
P3, N=312, Active, not recruiting, Sponsor: Children's Oncology Group
Trial completion date: Dec 2030 --> Jun 2023 Trial completion date: Sep 2025 --> Jun 2024 | Trial primary completion date: Sep 2025 --> Jun 2024
- | thioguanine / Generic mfg.
Enrollment closed: Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (clinicaltrials.gov) - May 3, 2022
P3, N=312, Active, not recruiting, Sponsor: Children's Oncology Group
Trial completion date: Sep 2025 --> Jun 2024 | Trial primary completion date: Sep 2025 --> Jun 2024 Recruiting --> Active, not recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 22, 2022
P3, N=670, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial completion date: Jun 2022 --> Dec 2030
- | thioguanine / Generic mfg.
Trial primary completion date: Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (clinicaltrials.gov) - Mar 22, 2022
P3, N=312, Recruiting, Sponsor: Children's Oncology Group
Trial completion date: Jun 2022 --> Dec 2030 Trial primary completion date: Jun 2023 --> Sep 2025
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 2, 2021
P3, N=670, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2023 --> Sep 2025 Trial primary completion date: Dec 2022 --> Jun 2021
- | Mylotarg (gemtuzumab ozogamicin) / Pfizer
Trial completion date: AAML0531: Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Oct 26, 2020
P3, N=1070, Completed, Sponsor: Children's Oncology Group
Trial primary completion date: Dec 2022 --> Jun 2021 Trial completion date: Aug 2013 --> Sep 2020
- | thioguanine / Generic mfg.
Trial primary completion date: Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (clinicaltrials.gov) - Sep 19, 2020
P3, N=256, Recruiting, Sponsor: Children's Oncology Group
Trial completion date: Aug 2013 --> Sep 2020 Trial primary completion date: Mar 2023 --> Jun 2023
- | Xospata (gilteritinib) / Astellas, Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Mylotarg (gemtuzumab ozogamicin) / Pfizer
Trial completion date, Trial primary completion date: A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (clinicaltrials.gov) - Sep 19, 2020
P3, N=1400, Recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Mar 2023 --> Jun 2023 Trial completion date: Feb 2025 --> Sep 2027 | Trial primary completion date: Feb 2025 --> Sep 2027
- | Xospata (gilteritinib) / Astellas, Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Mylotarg (gemtuzumab ozogamicin) / Pfizer
Enrollment open: A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (clinicaltrials.gov) - Jul 22, 2020
P3, N=1400, Recruiting, Sponsor: Children's Oncology Group
Trial completion date: Feb 2025 --> Sep 2027 | Trial primary completion date: Feb 2025 --> Sep 2027 Not yet recruiting --> Recruiting
- | dasatinib / Generic mfg.
Trial completion: AALL0622: Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 13, 2020
P2/3, N=63, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Enrollment closed: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Apr 6, 2020
P3, N=1895, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Completed --> Active, not recruiting
- | dasatinib / Generic mfg.
Enrollment closed, Trial completion date: AALL0622: Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 1, 2020
P2/3, N=63, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting Completed --> Active, not recruiting | Trial completion date: Sep 2015 --> Mar 2020
- | lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Enrollment closed: AALL0631: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 24, 2020
P3, N=218, Active, not recruiting, Sponsor: Children's Oncology Group
Completed --> Active, not recruiting | Trial completion date: Sep 2015 --> Mar 2020 Completed --> Active, not recruiting
- | thioguanine / Generic mfg.
Trial primary completion date: Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (clinicaltrials.gov) - Mar 13, 2020
P3, N=256, Recruiting, Sponsor: Children's Oncology Group
Completed --> Active, not recruiting Trial primary completion date: Mar 2022 --> Mar 2023
- | Xospata (gilteritinib) / Astellas, Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Mylotarg (gemtuzumab ozogamicin) / Pfizer
New P3 trial: A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (clinicaltrials.gov) - Mar 3, 2020
P3, N=1400, Not yet recruiting, Sponsor: Children's Oncology Group
- | bortezomib / Generic mfg., sorafenib / Generic mfg.
Enrollment closed, Trial completion date: AAML1031: Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 23, 2019
P3, N=1641, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Mar 2022 --> Mar 2023 Completed --> Active, not recruiting | Trial completion date: Mar 2019 --> Sep 2027
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment closed: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 3, 2019
P3, N=598, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting | Trial completion date: Mar 2019 --> Sep 2027 Recruiting --> Active, not recruiting
- | Trial completion: Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma (clinicaltrials.gov) - Aug 6, 2019
P3, N=393, Completed, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Leunase (L-asparaginase) / Kyowa Kirin, Kidrolase (L-asparaginase) / Jazz, Merck (MSD), Spectrila (asparaginase Escherichia coli) / Medac
Trial completion: AALL07P2: Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 6, 2019
P=N/A, N=59, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | bortezomib / Generic mfg., sorafenib / Generic mfg.
Trial completion: AAML1031: Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 20, 2019
P3, N=1644, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | bortezomib / Generic mfg., sorafenib / Generic mfg.
Trial primary completion date: AAML1031: Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 13, 2018
P3, N=1750, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Dec 2018 --> Mar 2019
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 13, 2018
P3, N=598, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2018 --> Mar 2019 Trial primary completion date: Mar 2022 --> Oct 2022
- | Enrollment change, Trial withdrawal: Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Nov 14, 2018
P2, N=0, Withdrawn, Sponsor: University of Washington
Trial primary completion date: Mar 2022 --> Oct 2022 N=71 --> 0 | Not yet recruiting --> Withdrawn
- | thioguanine / Generic mfg.
Trial primary completion date: Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (clinicaltrials.gov) - Aug 16, 2018
P3, N=256, Recruiting, Sponsor: Children's Oncology Group
N=71 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Dec 2019 --> Mar 2022
- | bortezomib / Generic mfg., sorafenib / Generic mfg.
Trial primary completion date: AAML1031: Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 14, 2018
P3, N=1750, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2019 --> Mar 2022 Trial primary completion date: Sep 2018 --> Dec 2018
- | Rituxan (rituximab) / Roche
Trial completion date, Trial primary completion date: Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 24, 2018
P2, N=78, Active, not recruiting, Sponsor: Asan Medical Center
Trial primary completion date: Sep 2018 --> Dec 2018 Trial completion date: Oct 2017 --> Jan 2019 | Trial primary completion date: Oct 2017 --> Jan 2018
- | lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Trial completion, Trial completion date, Trial primary completion date: AALL0631: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 17, 2018
P3, N=218, Completed, Sponsor: Children's Oncology Group
Trial completion date: Oct 2017 --> Jan 2019 | Trial primary completion date: Oct 2017 --> Jan 2018 Active, not recruiting --> Completed | Trial completion date: Sep 2018 --> Dec 2017 | Trial primary completion date: Sep 2018 --> Sep 2017
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Trial completion: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Jun 15, 2018
P3, N=1895, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Sep 2018 --> Dec 2017 | Trial primary completion date: Sep 2018 --> Sep 2017 Active, not recruiting --> Completed
- | Trial completion date, Trial primary completion date: Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Apr 23, 2018
P2, N=71, Not yet recruiting, Sponsor: University of Washington
Active, not recruiting --> Completed Trial completion date: Apr 2021 --> Jul 2021 | Trial primary completion date: Apr 2020 --> Jul 2020
- | Trial initiation date, Trial primary completion date: Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Jan 2, 2018
P2, N=71, Not yet recruiting, Sponsor: University of Washington
Trial completion date: Apr 2021 --> Jul 2021 | Trial primary completion date: Apr 2020 --> Jul 2020 Initiation date: Dec 2017 --> Apr 2018 | Trial primary completion date: Oct 2019 --> Apr 2020
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 13, 2017
P3, N=598, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Dec 2017 --> Apr 2018 | Trial primary completion date: Oct 2019 --> Apr 2020 Trial primary completion date: Apr 2018 --> Mar 2022
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Trial primary completion date: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Dec 12, 2017
P3, N=1895, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Apr 2018 --> Mar 2022 Trial primary completion date: Aug 2013 --> Sep 2017
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Trial primary completion date: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Oct 16, 2017
P3, N=1895, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Aug 2013 --> Sep 2017 Trial primary completion date: Sep 2017 --> Aug 2013
- | Trial initiation date, Trial primary completion date: Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Aug 10, 2017
P2, N=71, Not yet recruiting, Sponsor: University of Washington
Trial primary completion date: Sep 2017 --> Aug 2013 Initiation date: Jul 2017 --> Oct 2017 | Trial primary completion date: Jul 2019 --> Oct 2019
- | bortezomib / Generic mfg., sorafenib / Generic mfg.
Enrollment closed: AAML1031: Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 9, 2017
P3, N=1750, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Jul 2017 --> Oct 2017 | Trial primary completion date: Jul 2019 --> Oct 2019 Recruiting --> Active, not recruiting
- | Rituxan (rituximab) / Roche
Enrollment closed, Trial primary completion date: Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 21, 2017
P2, N=78, Active, not recruiting, Sponsor: Asan Medical Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Oct 2017
- | bortezomib / Generic mfg., sorafenib / Generic mfg.
Trial primary completion date: AAML1031: Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 17, 2017
P3, N=1750, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Oct 2017 Trial primary completion date: Sep 2017 --> Sep 2018
- | bortezomib / Generic mfg., sorafenib / Generic mfg.
Trial primary completion date: AAML1031: Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 23, 2017
P3, N=1750, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2017 --> Sep 2018 Trial primary completion date: Jun 2017 --> Sep 2017
- | Trial initiation date: Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Apr 26, 2017
P2, N=71, Not yet recruiting, Sponsor: University of Washington
Trial primary completion date: Jun 2017 --> Sep 2017 Initiation date: Jan 2017 --> Jul 2017